ArticleJournal of gastrointestinal oncology2016
Impressive response to dual
Article in Journal of gastrointestinal oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies.ESMO gastrointestinal oncology · 2025Review
- Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets.ESMO open · 2024Review
- Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.Cancers · 2024Review
- Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy.Annals of hepato-biliary-pancreatic surgery · 2023Review
- Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.International journal of molecular sciences · 2022Review
- Precision Medicine in Cholangiocarcinoma: Past, Present, and Future.Life (Basel, Switzerland) · 2022Review
- Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma.Journal of immunotherapy and precision oncology · 2022Article
- Current status of liver transplantation for cholangiocarcinoma.World journal of gastrointestinal surgery · 2022Review
- Moving forward in the treatment of cholangiocarcinoma.World journal of gastrointestinal oncology · 2021Review
- Article
- Review
- Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.Expert opinion on investigational drugs · 2021Review
- Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Review
- Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.Cancers · 2020Review
- Systemic treatment options for advanced biliary tract carcinoma.Journal of gastroenterology · 2020Review
- Third-line sunitinib treatment in aCancer biology & therapy · 2020Review
- New Treatment Options for Advanced Biliary Tract Cancer.Current treatment options in oncology · 2020Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) typically presents at an advanced stage and is associated with a poor oncological outcome. The median survival for metastatic ICC is less than 1 year with standard chemotherapy. ICC is associated with distinct oncogenic drivers including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.